Skip to main content
Erschienen in: Clinical & Experimental Metastasis 6/2020

24.10.2020 | Research Paper

The rise of metastatic bone disease in Ireland

verfasst von: Fergus J. McCabe, Dima Y. Jadaan, Mutaz M. Jadaan, John P. McCabe

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

To describe the expected rise of metastatic bone disease in Ireland, the relative primary types, and the locations of spread within the skeleton. This was a population-based epidemiological study using cancer registry data. We included patients with known metastatic cancer to bone, within 1 year of the primary diagnosis, during the years 1994 to 2012 inclusive. Our main outcome measures were age-specific, gender-specific and age-standardised incidence rates of bone metastasis, primary types and metastatic location within the skeleton. There were 14,495 recognised cases of bone metastasis in Ireland, 1994–2012 inclusive. Cases consistently rose over the time period, with 108% case increase and 51% age-standardised incidence rise. Annual percentage change increased across both genders and over all age groups. Most of this rise was not due to demographic population change. Breast, prostate and lung accounted for the majority of primary types. GI cancers were the fourth most common primary type. There were proportional increases in breast and lung, with proportional decreases in prostate. The spine was the major metastatic site. Bone metastasis is a significant and rising healthcare concern in Ireland. This rise is disproportionate to demographic changes. Breast, prostate and lung cancers account for the majority. GI cancers are implicated in an unexpectedly high number of cases. Spine is the most common location of bony metastasis, especially at presentation. Prudent healthcare planning is necessitated to prepare for the growing consequences of bone metastasis in cancer patients.
Literatur
1.
Zurück zum Zitat Clines GA, Guise TA (2008) Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 10:e7CrossRef Clines GA, Guise TA (2008) Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 10:e7CrossRef
2.
Zurück zum Zitat Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M (2014) Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 74:210–216CrossRef Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M (2014) Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 74:210–216CrossRef
3.
Zurück zum Zitat Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277CrossRef Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277CrossRef
4.
Zurück zum Zitat Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176CrossRef Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176CrossRef
5.
Zurück zum Zitat Harel R, Angelov L (2010) Spine metastases: current treatments and future directions. Eur J Cancer 46:2696–2707CrossRef Harel R, Angelov L (2010) Spine metastases: current treatments and future directions. Eur J Cancer 46:2696–2707CrossRef
6.
Zurück zum Zitat Baek YH, Jeon HL, Oh IS, Yang H, Park J, Shin JY (2019) Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: a 12-year longitudinal nationwide healthcare database study. Cancer Epidemiol 61:104–110CrossRef Baek YH, Jeon HL, Oh IS, Yang H, Park J, Shin JY (2019) Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: a 12-year longitudinal nationwide healthcare database study. Cancer Epidemiol 61:104–110CrossRef
7.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRef
8.
Zurück zum Zitat National Cancer Registry (2019a) Cancer incidence projections for Ireland 2020–2045. National Cancer Registry, Cork National Cancer Registry (2019a) Cancer incidence projections for Ireland 2020–2045. National Cancer Registry, Cork
9.
Zurück zum Zitat Central Statistics Office (2020) Vital Statistics Yearly Summary 2019. Central Statistics Office (2020) Vital Statistics Yearly Summary 2019.
10.
Zurück zum Zitat Marasigan V, Perry I, Bennett K, Balanda K, Capewell S, O’ Flaherty M, Kabir Z, (2020) Explaining the fall in Coronary Heart Disease mortality in the Republic of Ireland between 2000 and 2015 - IMPACT modelling study. Int J Cardiol 310:159–161CrossRef Marasigan V, Perry I, Bennett K, Balanda K, Capewell S, O’ Flaherty M, Kabir Z, (2020) Explaining the fall in Coronary Heart Disease mortality in the Republic of Ireland between 2000 and 2015 - IMPACT modelling study. Int J Cardiol 310:159–161CrossRef
11.
Zurück zum Zitat National Cancer Registry (2019b) Cancer in Ireland 1994–2017 with estimates for 2017–2019: Annual report of the National Cancer Registry. National Cancer Registry, Cork National Cancer Registry (2019b) Cancer in Ireland 1994–2017 with estimates for 2017–2019: Annual report of the National Cancer Registry. National Cancer Registry, Cork
12.
Zurück zum Zitat National Cancer Registry (2012) Completeness at the Irish National Cancer Registry. National Cancer Registry, Cork National Cancer Registry (2012) Completeness at the Irish National Cancer Registry. National Cancer Registry, Cork
13.
Zurück zum Zitat Cetin K, Christiansen CF, Sværke C, Jacobsen JB, Sørensen HT (2015) Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval. BMJ Open 5:e007702CrossRef Cetin K, Christiansen CF, Sværke C, Jacobsen JB, Sørensen HT (2015) Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval. BMJ Open 5:e007702CrossRef
14.
Zurück zum Zitat Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184:162–167CrossRef Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184:162–167CrossRef
15.
Zurück zum Zitat Svensson E, Christiansen CF, Ulrichsen SP, Rørth MR, Sørensen HT (2017) Survival after bone metastasis by primary cancer type: a Danish population-based cohort study. BMJ Open 7:e016022CrossRef Svensson E, Christiansen CF, Ulrichsen SP, Rørth MR, Sørensen HT (2017) Survival after bone metastasis by primary cancer type: a Danish population-based cohort study. BMJ Open 7:e016022CrossRef
16.
Zurück zum Zitat Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391:1023–1075CrossRef Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391:1023–1075CrossRef
17.
Zurück zum Zitat Yang H-L, Liu T, Wang X-M, Xu Y, Deng S-M (2011) Diagnosis of bone metastases: a meta-analysis comparing 18 FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 21:2604–2617CrossRef Yang H-L, Liu T, Wang X-M, Xu Y, Deng S-M (2011) Diagnosis of bone metastases: a meta-analysis comparing 18 FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 21:2604–2617CrossRef
18.
Zurück zum Zitat Piccioli A, Maccauro G, Spinelli MS, Biagini R, Rossi B (2015) Bone metastases of unknown origin: epidemiology and principles of management. J Orthop Traumatol 16:81–86CrossRef Piccioli A, Maccauro G, Spinelli MS, Biagini R, Rossi B (2015) Bone metastases of unknown origin: epidemiology and principles of management. J Orthop Traumatol 16:81–86CrossRef
19.
Zurück zum Zitat Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K (2014) Metastatic sites and survival in lung cancer. Lung Cancer 86:78–84CrossRef Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K (2014) Metastatic sites and survival in lung cancer. Lung Cancer 86:78–84CrossRef
22.
Zurück zum Zitat Lipfert FW, Wyzga RE (2019) Longitudinal relationships between lung cancer mortality rates, smoking, and ambient air quality: a comprehensive review and analysis. Crit Rev Toxicol 49:790–818CrossRef Lipfert FW, Wyzga RE (2019) Longitudinal relationships between lung cancer mortality rates, smoking, and ambient air quality: a comprehensive review and analysis. Crit Rev Toxicol 49:790–818CrossRef
23.
Zurück zum Zitat Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6249sCrossRef Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6249sCrossRef
24.
Zurück zum Zitat Parameswaran R, Shulin HuJ, Min En N, Tan WB, Yuan NK (2017) Patterns of metastasis in follicular thyroid carcinoma and the difference between early and delayed presentation. Ann R Coll Surg Engl 99:151–154CrossRef Parameswaran R, Shulin HuJ, Min En N, Tan WB, Yuan NK (2017) Patterns of metastasis in follicular thyroid carcinoma and the difference between early and delayed presentation. Ann R Coll Surg Engl 99:151–154CrossRef
25.
Zurück zum Zitat Krishnamurthy GT, Tubis M, Hiss J, Blahd WH (1977) Distribution pattern of metastatic bone disease. A need for total body skeletal image. JAMA 237:2504–2506CrossRef Krishnamurthy GT, Tubis M, Hiss J, Blahd WH (1977) Distribution pattern of metastatic bone disease. A need for total body skeletal image. JAMA 237:2504–2506CrossRef
26.
Zurück zum Zitat Tubiana-Hulin M (1991) Incidence, prevalence and distribution of bone metastases. Bone 12(Suppl 1):S9-10CrossRef Tubiana-Hulin M (1991) Incidence, prevalence and distribution of bone metastases. Bone 12(Suppl 1):S9-10CrossRef
27.
Zurück zum Zitat Organization WH (2004) ICD-10: international statistical classification of diseases and related health problems: tenth revision. Organization WH (2004) ICD-10: international statistical classification of diseases and related health problems: tenth revision.
28.
Zurück zum Zitat Sciubba DM, Gokaslan ZL, Suk I, Suki D, Maldaun MVC, McCutcheon IE, Nader R, Theriault R, Rhines LD, Shehadi JA (2007) Positive and negative prognostic variables for patients undergoing spine surgery for metastatic breast disease. Eur Spine J 16:1659–1667CrossRef Sciubba DM, Gokaslan ZL, Suk I, Suki D, Maldaun MVC, McCutcheon IE, Nader R, Theriault R, Rhines LD, Shehadi JA (2007) Positive and negative prognostic variables for patients undergoing spine surgery for metastatic breast disease. Eur Spine J 16:1659–1667CrossRef
29.
Zurück zum Zitat Pereira J, Body JJ, Gunther O, Sleeboom H, Hechmati G, Maniadakis N, Terpos E, Acklin YP, Finek J, von Moos R (2016) Cost of skeletal complications from bone metastases in six European countries. J Med Econ 19:611–618CrossRef Pereira J, Body JJ, Gunther O, Sleeboom H, Hechmati G, Maniadakis N, Terpos E, Acklin YP, Finek J, von Moos R (2016) Cost of skeletal complications from bone metastases in six European countries. J Med Econ 19:611–618CrossRef
30.
Zurück zum Zitat Tipsmark LS, Bünger CE, Wang M, Morgen SS, Dahl B, Søgaard R (2015) Healthcare costs attributable to the treatment of patients with spinal metastases: a cohort study with up to 8 years follow-up. BMC Cancer 15:354CrossRef Tipsmark LS, Bünger CE, Wang M, Morgen SS, Dahl B, Søgaard R (2015) Healthcare costs attributable to the treatment of patients with spinal metastases: a cohort study with up to 8 years follow-up. BMC Cancer 15:354CrossRef
31.
Zurück zum Zitat Robine J-M, Saito Y, Jagger C (2009) The relationship between longevity and healthy life expectancy. Qual Ageing Older Adults 10:5CrossRef Robine J-M, Saito Y, Jagger C (2009) The relationship between longevity and healthy life expectancy. Qual Ageing Older Adults 10:5CrossRef
32.
Zurück zum Zitat Barzilai O, Boriani S, Fisher CG, Sahgal A, Verlaan JJ, Gokaslan ZL, Lazary A, Bettegowda C, Rhines LD, Laufer I (2019) Essential concepts for the management of metastatic spine disease: what the surgeon should know and practice. Glob Spine J 9:98S-107SCrossRef Barzilai O, Boriani S, Fisher CG, Sahgal A, Verlaan JJ, Gokaslan ZL, Lazary A, Bettegowda C, Rhines LD, Laufer I (2019) Essential concepts for the management of metastatic spine disease: what the surgeon should know and practice. Glob Spine J 9:98S-107SCrossRef
33.
Zurück zum Zitat Wouterse B, Huisman M, Meijboom BR, Deeg DJH, Polder JJ (2015) The effect of trends in health and longevity on health services use by older adults. BMC Health Serv Res 15:574CrossRef Wouterse B, Huisman M, Meijboom BR, Deeg DJH, Polder JJ (2015) The effect of trends in health and longevity on health services use by older adults. BMC Health Serv Res 15:574CrossRef
34.
Zurück zum Zitat Johnson CN, Gurich RW, Pavey GJ, Thompson MJ (2019) Contemporary management of appendicular skeletal metastasis by primary tumor type. J Am Acad Orthop Surg 27:345–355CrossRef Johnson CN, Gurich RW, Pavey GJ, Thompson MJ (2019) Contemporary management of appendicular skeletal metastasis by primary tumor type. J Am Acad Orthop Surg 27:345–355CrossRef
35.
Zurück zum Zitat Yahanda AT, Buchowski JM, Wegner AM (2019) Treatment, complications, and outcomes of metastatic disease of the spine: from Patchell to PROMIS. Ann Transl Med 7:216CrossRef Yahanda AT, Buchowski JM, Wegner AM (2019) Treatment, complications, and outcomes of metastatic disease of the spine: from Patchell to PROMIS. Ann Transl Med 7:216CrossRef
36.
Zurück zum Zitat Turpin A, Duterque-Coquillaud M, Vieillard MH (2020) Bone metastasis: current state of play. Transl Oncol 13:308–320CrossRef Turpin A, Duterque-Coquillaud M, Vieillard MH (2020) Bone metastasis: current state of play. Transl Oncol 13:308–320CrossRef
37.
Zurück zum Zitat Zheng X-Q, Huang J-F, Lin J-L, Chen L, Zhou T-T, Chen D, Lin D-D, Shen J-F, Wu A-M (2019) Incidence, prognostic factors, and a nomogram of lung cancer with bone metastasis at initial diagnosis: a population-based study. Transl Lung Cancer Res 8:367CrossRef Zheng X-Q, Huang J-F, Lin J-L, Chen L, Zhou T-T, Chen D, Lin D-D, Shen J-F, Wu A-M (2019) Incidence, prognostic factors, and a nomogram of lung cancer with bone metastasis at initial diagnosis: a population-based study. Transl Lung Cancer Res 8:367CrossRef
38.
Zurück zum Zitat D’Oronzo S, Coleman R, Brown J, Silvestris F (2019) Metastatic bone disease: Pathogenesis and therapeutic options: up-date on bone metastasis management. J Bone Oncol 15:004–004PubMed D’Oronzo S, Coleman R, Brown J, Silvestris F (2019) Metastatic bone disease: Pathogenesis and therapeutic options: up-date on bone metastasis management. J Bone Oncol 15:004–004PubMed
39.
Zurück zum Zitat Curtin M, Piggott RP, Murphy EP, Munigangaiah S, Baker JF, McCabe JP, Devitt A (2017) Spinal metastatic disease: a review of the role of the multidisciplinary team. Orthop Surg 9:145–151CrossRef Curtin M, Piggott RP, Murphy EP, Munigangaiah S, Baker JF, McCabe JP, Devitt A (2017) Spinal metastatic disease: a review of the role of the multidisciplinary team. Orthop Surg 9:145–151CrossRef
40.
Zurück zum Zitat Murphy CC, Yang YC (2018) Use of age-period-cohort analysis in cancer epidemiology research. Curr Epidemiol Rep 5:418–431CrossRef Murphy CC, Yang YC (2018) Use of age-period-cohort analysis in cancer epidemiology research. Curr Epidemiol Rep 5:418–431CrossRef
Metadaten
Titel
The rise of metastatic bone disease in Ireland
verfasst von
Fergus J. McCabe
Dima Y. Jadaan
Mutaz M. Jadaan
John P. McCabe
Publikationsdatum
24.10.2020
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 6/2020
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-020-10059-7

Weitere Artikel der Ausgabe 6/2020

Clinical & Experimental Metastasis 6/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.